Congenital Adrenal Hyperplasia: The Hormonal Condition Affecting Gender and Development
Few medical conditions demonstrate as powerfully as congenital adrenal hyperplasia how profoundly hormones shape human development — from the moment of conception, through the first days of life, and across the entire lifespan. This inherited disorder of the adrenal glands does not simply disrupt hormone levels. In its most severe forms, it can threaten a newborn’s life within days of birth, alter the development of external genitalia in female babies before they are even born, drive premature puberty in toddlers, and cause fertility problems and metabolic complications in adults. CAH is far more complex and far-reaching than most people realise — and in December 2024, it gained its first new FDA-approved treatment in 70 years.
What Is Congenital Adrenal Hyperplasia?
Congenital adrenal hyperplasia is a group of rare inherited autosomal recessive disorders characterised by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: corticosteroids, which gauge the body’s response to illness or injury; mineralocorticoids, which regulate salt and water levels; and androgens, which are male sex hormones. An enzyme deficiency makes the body unable to produce one or more of these hormones, which in turn results in the overproduction of another type of hormone precursor in order to compensate for the loss. Frontiers
The word “congenital” means present from birth. The word “hyperplasia” means the overgrowth of tissue — in this case, the adrenal glands enlarge because they receive constant stimulation from the pituitary, which is desperately signalling them to produce more cortisol that they cannot make. The most common cause of CAH is the absence of the enzyme 21-hydroxylase, which accounts for approximately 95% of all CAH cases. NCBI
Classic and Non-Classic CAH
CAH exists on a spectrum defined by the severity of the enzyme deficiency. Classic CAH is rare but serious. Doctors usually diagnose it through tests at birth or shortly after birth. In many countries, newborns are tested for classic CAH using a blood test from a heel prick. Diabetes Journals
Within classic CAH, there are two further subtypes. Salt-wasting CAH is the most severe form, in which the body cannot produce either cortisol or aldosterone in adequate amounts. About 75% of people with classical CAH due to 21-hydroxylase deficiency also have a deficiency of aldosterone, leading to the inability to retain salt and water. Without aldosterone, the kidneys cannot hold onto sodium, leading to a life-threatening salt-wasting crisis in the first weeks of life. Simple virilising CAH is a slightly milder form where aldosterone production is sufficient but cortisol and androgen control remain severely disrupted. Frontiers
Non-classic CAH is a milder, later-presenting form. Non-classic CAH is a more common, milder form that presents late after puberty. In this form, enough enzyme activity remains to prevent a salt-wasting crisis, but androgen excess still develops gradually, causing symptoms that emerge during childhood, adolescence, or adulthood. NCBI
How the Enzyme Deficiency Causes Every Symptom
Understanding the impact of 21-hydroxylase deficiency requires understanding the adrenal hormone production pathway. The adrenal glands normally convert cholesterol into cortisol and aldosterone through a series of enzymatic steps. The 21-hydroxylase enzyme is essential for this conversion. When it is absent or severely reduced, the production line backs up. The precursor molecules that cannot be converted into cortisol accumulate instead — and the body shunts them down an alternative pathway into androgens. The result is a simultaneous deficiency of cortisol and aldosterone alongside a massive excess of androgens.
Reduced ability to synthesise cortisol in classic CAH leads to a loss of negative feedback on the HPA axis, resulting in increased production of corticotropin-releasing factor (CRF), ACTH, and androgens. The pituitary gland, sensing the cortisol deficiency, releases escalating amounts of ACTH to drive the adrenal glands harder — but harder work only produces more androgens, not more cortisol. This is the vicious cycle at the heart of the condition. Expert Market Research
The Salt-Wasting Crisis: A Neonatal Emergency
In severe salt-wasting CAH, the first weeks of life represent a window of extreme danger, particularly for male infants. Female infants are often identified earlier because their external genitalia appear ambiguous at birth — a visible signal that something is wrong. Male infants with salt-wasting CAH look entirely normal at birth, and without newborn screening, they may be sent home undiagnosed. Genital ambiguity in female newborns with CAH allows for early diagnosis, while males are usually asymptomatic at birth and are generally diagnosed after a life-threatening adrenal crisis, or they die unsuspected. PubMed Central
The salt-wasting crisis typically strikes between five days and four weeks of life. Vomiting, poor feeding, weight loss, severe dehydration, dangerously low blood sodium, and collapse rapidly escalate. Without emergency treatment with intravenous hydrocortisone, saline, and fludrocortisone, the infant can die within days.
How CAH Affects Gender and Development
The excess of androgens in CAH has profoundly different effects depending on biological sex and the timing of exposure. Females with severe or classic virilising CAH due to 21-hydroxylase deficiency will most likely have ambiguous or atypical external genitalia — masculinisation or virilisation — although they are genetically female and will have normal internal reproductive organs. Males with this type of CAH will not have ambiguous genitalia. Both genders can experience other symptoms such as early onset of puberty, fast body growth, and premature completion of growth leading to short stature if they are not diagnosed and treated in early life. Frontiers
The external genital ambiguity in female CAH infants occurs because high androgen levels during foetal development partially masculinise the genitalia — creating an enlarged clitoris, fused labia, and in some cases a common urogenital opening. Internally, the uterus and ovaries develop normally, and with appropriate treatment, fertility is possible.
In adolescent girls, irregular menses can develop, while testicular adrenal tumours can arise in boys. Both sexes can develop hypogonadism and impaired fertility in adulthood. The ongoing androgen excess if inadequately treated also causes rapid early bone growth in childhood, leading paradoxically to short adult height because the growth plates fuse prematurely. DelveInsight
Diagnosis: Newborn Screening and Hormone Testing
By identifying babies with severe salt-wasting CAH before they develop adrenal crises, newborn screening reduces morbidity and mortality, especially among affected boys. Diagnosis is based on elevated levels of 17-hydroxyprogesterone (17-OHP), the preferred substrate for steroid 21-hydroxylase. This blood test from a heel-prick sample taken in the first days of life is now routine in many countries. Wikipedia
In older children and adults being evaluated for non-classic CAH, the ACTH stimulation test is the gold standard — measuring the rise in 17-OHP and other hormonal precursors after an injection of synthetic ACTH. Genetic testing confirming a CYP21A2 gene mutation provides definitive diagnosis. Bone age X-rays assess how much premature skeletal maturation has occurred.
For more information on rare genetic disorders and global health resources, visit the World Health Organization and ObserverVoice.com.
Treatment: Old Standard and a Historic New Option
For decades, the only treatment for CAH was glucocorticoids — hydrocortisone in children, or prednisolone and dexamethasone in adults — taken daily to replace the missing cortisol. The problem is profound: treatment involves use of glucocorticoids to replace the missing cortisol, but supraphysiologic doses have typically been required to also control the excess androgens. High glucocorticoid exposure can result in multiple adverse outcomes including reduced bone density, obesity, insulin resistance, type 2 diabetes, hyperlipidaemia, and hypertension. This means that for 70 years, adequately treating the androgen excess almost inevitably came at the price of steroid side effects. DelveInsight
This changed dramatically in December 2024. Crinecerfont (Crenessity, Neurocrine Biosciences) received FDA approval as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and paediatric patients four years of age and older with classic CAH. This decision marks crinecerfont as the first new treatment option for these patients in 70 years. ResearchGate
Crinecerfont is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that acts in the pituitary to decrease adrenal androgen production independently of glucocorticoids. Antagonism of CRF1 receptors in the pituitary decreases ACTH levels, which in turn decreases the production of adrenal androgens. The clinical data demonstrate that lowering adrenal androgen levels with crinecerfont enables lower, more physiologic dosing of glucocorticoids to replace missing cortisol. Medscape
In plain terms, crinecerfont addresses the root problem at the pituitary level — reducing the runaway ACTH signal that drives androgen overproduction — allowing patients to take much lower, safer doses of steroids. Salt-wasting CAH also requires fludrocortisone replacement for aldosterone deficiency, taken alongside glucocorticoids throughout life.
Frequently Asked Questions
Q1. Is CAH always identified at birth? Classic salt-wasting CAH is identified through newborn screening programmes in most high-income countries. Female infants may be identified earlier because external genital ambiguity is visible at birth. Male infants with salt-wasting CAH look physically normal and are at greatest risk of being sent home undiagnosed without routine screening. Non-classic CAH may not present until puberty or adulthood, when symptoms of androgen excess emerge.
Q2. Can females with CAH have children? Yes, though fertility may be reduced — particularly in females with classic CAH who have higher residual androgen levels. With well-controlled CAH and appropriate hormone management, pregnancy is possible. Fertility treatment is sometimes needed. Prenatal counselling is strongly advised for parents with CAH who are planning pregnancy, since genetic counselling can assess the risk of an affected child.
Q3. Does CAH affect gender identity? Research has explored this question extensively. Studies show that the majority of females with CAH identify as female. However, elevated prenatal androgen exposure is associated with a higher rate of gender dysphoria and gender non-conformity compared to the general female population. Each individual’s experience is unique, and open, supportive conversation with specialist teams is central to care.
Q4. What happens during illness or injury in someone with CAH? Patients with CAH cannot mount a normal cortisol stress response. During illness, fever, injury, or surgery, the body’s cortisol demand increases dramatically. People with CAH must carry emergency hydrocortisone for injection and are taught to triple their oral dose during significant illness — a practice called sick-day rules. Failure to do so can precipitate a life-threatening adrenal crisis requiring immediate hospital treatment.
Q5. Is non-classic CAH serious? Non-classic CAH is much milder than classic CAH — it is not life-threatening and does not cause genital ambiguity at birth. However, it can cause significant symptoms including early pubic hair development in children, acne, excess facial or body hair, irregular periods, reduced fertility, and in some cases anxiety about appearance and development. Treatment with low-dose glucocorticoids is used when symptoms are troublesome.
References
- NORD — Congenital Adrenal Hyperplasia
- Cleveland Clinic — Congenital Adrenal Hyperplasia: Symptoms, Causes and Treatment
- Pharmacy Times — FDA Approves Crinecerfont for Adult and Paediatric Patients with Congenital Adrenal Hyperplasia, December 2024
- Medscape — New Data Back Crinecerfont in Congenital Adrenal Hyperplasia, 2025
- PMC / NIH — Newborn Screening for CAH: Challenges and Opportunities
- WHO — Rare Diseases Fact Sheet
Disclaimer
This article adapts publicly available information from WHO’s Rare Diseases page and other publicly available sources on congenital adrenal hyperplasia, CYP21A2 gene mutations, adrenal hormone disorders, and steroid replacement therapy. This content is for informational and educational purposes only and does not constitute medical advice. Diagnosis and management of CAH should always be guided by a qualified paediatric endocrinologist or specialist in endocrinology and metabolism. ObserverVoice.com is a news and information platform — not a healthcare provider.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
